×
InDrive has big plans to become a global ‘super app’ where others have failed | TechCrunch

InDrive has big plans to become a global ‘super app’ where others have failed | TechCrunch

InDrive, known for its bidding-based ride-hailing model across Asia and Latin America, is rolling out a “super-app” strategy aimed at frontier markets — expanding beyond cabs to deliver daily essentials to its users.

Beginning with grocery deliveries in Kazakhstan, InDrive plans to expand into multiple verticals over the next 12 months across its top markets, including Brazil, Colombia, Egypt, Pakistan, Peru, and Mexico. The shift comes on the heels of more than 360 million app downloads and 6.5 billion transactions globally, cementing its position as the world’s second most-downloaded ride-hailing app, behind Uber, since 2022.

“If customers use you more frequently, then, of course, they stay longer, they’re more valuable in the ecosystem, and they’re just more loyal overall,” said Andries Smit, chief growth business officer at InDrive, in an exclusive interview.

InDrive chose grocery delivery as its first expansion move after seeing rapid growth in its delivery segment — with over 41 million orders completed worldwide in 2024 and more than 14 million in Q2 2025 alone — making it one of the fastest-scaling categories in the company’s portfolio.

The Mountain View, California-based company has launched its grocery delivery service in Kazakhstan, offering over 5,000 products with a 15-minute delivery promise. Early pilots in the Central Asian country yielded a net promoter score of 83% — signaling high customer satisfaction — and an average of five grocery orders per user per month, the company said.

Smit told TechCrunch that InDrive is using a dark store model for grocery deliveries in Kazakhstan, with most items focused on ready-to-eat meals and around 10% consisting of fresh products — part of a strategy to boost customer retention. He added that the model will vary in other regions, where the company is open to partnering locally, particularly in markets with a dense network of mom-and-pop stores.

Without sharing specifics, Smit said that the company has added 30% more dark stores in the country since August.

Techcrunch event

San Francisco
|
October 27-29, 2025

Why is Kazakhstan the first market?

InDrive currently operates in 982 cities across 48 countries globally and leads in eight of them. But then why has it picked Kazakhstan as the first market for its super-app move?

Smit told TechCrunch that the company decided to do so after seeing a “huge uptick” in consumers going digital in the country, which is the largest economy across Central Asia. InDrive also has its largest headcount in Kazakhstan, serving as a central hub for its R&D and operations.

InDrive did not disclose specific growth metrics for its operations in Kazakhstan. However, a recent report by Dealroom, published in collaboration with the government-backed tech park Astana Hub, noted that the company saw a 44% growth in the country over the past 12 months.

The report also valued Kazakhstan’s tech ecosystem at $26 billion — an 18-fold jump since 2019 — suggesting a sharp rise in local startup formation, funding, and digital services.

Image Credits:Dealroom

Kazakhstan already has grocery delivery apps to fulfill some of the demand. Nonetheless, InDrive wants to win the market predominantly with affordable pricing — aiming to be the Aldi of online groceries.

“There is access and inequality, and even access issues with some of the groceries,” said Smit. “Some of our cost-conscious consumers end up not buying from the right places or not buying the right goods, and they recognize that, but they feel they have no other choice.”

InDrive’s super-app: a differentiator or déjà vu

Many companies have tried to succeed with super apps. While some, like WeChat and Gojek, have found success, others — including Meta — have struggled to gain traction.

Smit, who worked with WeChat in his former role in 2016, experienced how the integrated experience on the Chinese app worked well. He told TechCrunch that, by leveraging his expertise and utilizing AI capabilities, InDrive plans to make its super-app strategy successful. The AI integration would help bring personalization to users and make services accessible to people with disabilities and those with lower literacy, he said.

InDrive’s Grocery Delivery service in KazakhstanImage Credits:InDrive

In November 2023, InDrive announced a venture and merger and acquisition arm to invest up to $100 million over the next few years. Smit told TechCrunch that of that venture, about 30% has already been deployed on the super-app strategy.

The company invested in Pakistan’s grocery startup, Krave Mart, in December as part of that venture. However, there is no concrete timeline on when InDrive’s app will offer grocery deliveries to users in Pakistan.

InDrive’s arch-rival Uber has also expanded its service portfolio, adding verticals like food delivery through Uber Eats in select markets. Smit said InDrive targets a different customer segment — one that Uber typically doesn’t serve — though there is some overlap in certain regions.

“By and large, we really support and play into a cost-conscious consumer,” he said.

India as a “puzzle” market

In addition to frontier markets including Kazakhstan, InDrive has been operating in India for some time, competing with Uber as well as homegrown players such as Ola and Rapido. However, the company has not picked up in the South Asian nation. Uber even piloted a version of InDrive’s bidding model in India, attempting to replicate the approach.

Data from Appfigures exclusively shared with TechCrunch shows that InDrive saw 1.07 million fewer downloads year-to-date compared to the same period in 2024 — a 22.6% decline. In contrast, Uber added 8.02 million downloads, up 60.6%, while Ola gained 1.55 million, a 13.2% increase. Rapido emerged as the fastest-growing player, with 14.9 million additional downloads — an 80.9% surge.

“India is a puzzle for us,” Smit told TechCrunch. “India is still growing, and we are focused… we’ve decided to focus very quickly on key cities where we really think we want to operate strongly.”

Ride-hailing app Uber, Ola, Rapido, InDrive downloads in India
Image Credits:Jagmeet Singh / TechCrunch

The company is testing different models, especially in the freight business, though it is known for allowing riders to haggle with drivers. These include different payment mechanisms for drivers to get paid daily and even go with a specific take rate, Smit said.

InDrive faced early challenges and saw limited success at first — even in markets like Pakistan, where it later became the leading ride-hailing platform following Uber’s exit.

“We’ve had sleeper markets where the markets sort of drifted, and then for whatever case, maybe one of the competitors falters,” Smit said.

More than a dozen riders and drivers in India told TechCrunch that safety concerns were a key reason they no longer prefer using InDrive. Some drivers said the app’s bidding model had been exploited by riders — and, in some cases, even by fellow drivers posing as riders to hassle their peers by aggressively haggling.

Smit said that the company prioritizes safety and customer service.

“Yes, we need to do a lot more in talking to this safety perception and in teaching and educating our drivers and passengers,” he said.

Next verticals in plans

InDrive plans to expand its super-app offering by launching new services tailored to local market needs. Smit told TechCrunch that these could include financial services. One example is already live in markets including Brazil and Mexico, where drivers can access small loans through the ride-hailing app. The company is exploring ways to extend this to passengers — and potentially to small businesses involved in deliveries, the executive added.

The company also plans to explore a service that enables micro-mobility, allowing its consumers to connect with local businesses and public transportation services.

“We want to be city-specific, and it could be a bouquet of different services,” Smit said. “We want to capture the key verticals that we have capability for, that we know and are very close to our core… But if we have no experience in running, for those kinds of services, we will definitely just partner with the right player.”

Source link
#InDrive #big #plans #global #super #app #failed #TechCrunch

suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As

that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As">Can Ozempic Treat Alcoholism? Here’s What You Should Know

Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders.

Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink.

Can Ozempic Treat Alcoholism? Here’s What You Should Know
                Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use disorders. Over the past few years, a growing base of evidence has suggested that GLP-1s can tamp down people’s unhealthy urges for alcohol, cocaine, and even vices like gambling. And earlier this month, researchers in Denmark published data from the first double-blinded, randomized, and placebo-controlled trial of semaglutide for alcohol use disorder in The Lancet. Over a 26-week period, the study found that people on semaglutide consumed less alcohol than those given a placebo and experienced noticeably fewer heavy drinking days when they did drink. © siamionau pavel via Shutterstock There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

 I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

 Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders? Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

 © Mohammed_Al_Ali via Shutterstock And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely. Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month? Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

 Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way. Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering? Shah: So there are a couple of things. These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

 © Sebastien Bozon/AFP via Getty If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect. Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now? Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

 So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.      #Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
© siamionau pavel via Shutterstock

There are other similar studies underway, including in the United States. Some are testing semaglutide for other kinds of substance use disorder, like opioids. Others are testing newer drugs like tirzepatide (a dual agonist that pairs GLP-1 with the hunger-related hormone GIP).

I reached out to an outside expert, Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, to talk about the emerging science surrounding GLP-1s and addiction treatment. We discussed the leading theory behind why GLP-1s can reduce addiction, his opinion of the recent Lancet trial, and what it will take for these drugs to be widely adopted as treatments for substance use disorders. The following has been lightly edited for clarity and grammar.

Ed Cara, Gizmodo: Do we have any sort of sense yet as to how or why GLP-1s seem to be working well against substance use disorders?

Asim Shah: So the craving, or pleasure, center of the brain is related to dopamine, which is a brain neurotransmitter. Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug. That’s the neurobiological mechanism of craving and pleasure, and it’s all the same mechanism.

The obesity medication Saxenda, made with liraglutide
© Mohammed_Al_Ali via Shutterstock

And incidentally, we found out that the people who were losing weight on these GLP-1s, they often also stopped smoking cigarettes and their addiction got better with alcohol. It was an incidental finding, but it’s something people are now trying to study more closely.

Gizmodo: Speaking of studies, what do you make of the newest trial published in The Lancet this month?

Shah: So this was a 26 week study, which had about 100 patients, half and half men and women both. In our world, 100 patients is a medium sized study; a larger one might usually have 300, 400, 600 patients. So this is a medium sized study, which is decent. It’s not bad. And in my opinion, it was done pretty well, not a lot of bias in the study that I saw.

Now, of course, this is not a definitive study. And you need to follow up with these patients after the weeks of study. We call these start-up studies, and they are what we base future, longer and bigger studies on. So it’s a good base, and there are other studies on the way.

Gizmodo: Broadly speaking, what are the questions that these longer and larger studies need to try answering?

Shah: So there are a couple of things.

These are different substances that people are looking at; one is alcohol, one smoking, the other is opiates. So the next studies we should be doing is to see whether GLP-1s like semaglutide can limit more than one of these addictions. Because the mechanism is the same mechanism for all the cravings and the addictions. So can it reduce all of these or just one if somebody is taking it?

Boxes of the GLP-1 medication Ozempic
© Sebastien Bozon/AFP via Getty

If we do keep seeing an effect here, it’s also important to know how quickly this happens and whether it can be sustained after you stop using a GLP-1. That’s why we have to follow people after these sorts of trials, to see if the effect can last after they stop taking the medication or if it requires people needing to stay on the drug for the effect.

Gizmodo: These sort of studies are happening. But what should be the current takeaway for people with these addictions and their doctor? Is this something that could be used in the real world right now?

Shah: Because they’re not approved right now, the takeaway should be that if you already have a current indication to take a GLP-1 which is for diabetes or obesity, certainly take it. If you also get an added advantage of stopping your smoking or alcohol use disorder, that is well and good because we don’t have approval for these disorders currently.

So in other words, if somebody comes to us and says, “Hey, I want to start these medicines for smoking cessation or alcohol use disorder,” we may not be able to prescribe it because there’s no approval. But they can be part of a study which is going on in some centers for those disorders. And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, that’s great, too.

#Ozempic #Treat #Alcoholism #Heresaddiction,Alcoholism,GLP-1s,Ozempic,Q&As
Bartesian is the Keurig of cocktails. After trying several automatic cocktail makers on the market, it was the only cocktail maker I could see fitting into my normal routine. It works like any capsule-style device, but with booze. You fill the Bartesian’s glass bottles with your liquor of choice, make sure there’s water in the reservoir, plop in a cocktail capsule (these typically cost $2-3), choose your drink strength, press “mix,” and then a drink comes out. (If you’ve got kids, the Bartesian Professional version comes with a lock that will stymie curious fingers.)

Do you need a Bartesian to make cocktails? Of course you don’t. You can dump tequila into sour mix anytime and call it a margarita. But perhaps you’d like to make an espresso martini, a blackberry margarita, and also a Long Island Iced Tea? The Bartesian is a sort of shortcut to a home bar, without having to store all the mixers—and a bit of a novelty. It will be fun, and silly, and the drinks are kind of fine in a Spring Break way: strong and sweet and with sometimes fun flavors. Don’t expect sophistication. Expect a bit of a party trick, the sort of thing that makes a summer a little more fun.

You’ll, of course, want a Bartesian coupon to make that fun more accessible. Luckily, the current Bartesian discount codes are good for up to 35% off.

Save up to 35% With a Bartesian Cocktail Subscription

Standard pods on the Bartesian come in packs of 8, for $20 to $25. But if you know you plan to use the cocktail machine often—garden parties, art gallery openings, a really cool barber shop, an interesting home life, Friday afternoon margaritaville—the easiest way to save on the Bartesian pods is to sign up for a cocktail subscription. No Bartesian subscription discount codes are required. Subscription boxes always cost $20, so get the ones that’d be otherwise expensive for a 20% discount—then get additional tiered discounts of Bartesian depending on volume and frequency. If you order often or in large quatnities, this can add up to 35% off the regular price.

Save 15% (Or More) When You Purchase a Cocktail Bundle

I can’t tell you what to do. But at current discounts on Bartesian cocktail bundles and add-ons, only a sucker buys a Bartesian as a standalone item. If you flip to the Bartesian bundles page, you can find multiple bundles that offer glassware and cocktail variety packs for about the same price as the machine by itself. The Mom Bundle in particular costs less than the Bartesian Pro machine by itself, but includes 8 margarita capsules and two glasses. As of April 2026, Bartesian is also offering a Mother’s Day deal, offering $100 off the Bartesian Pro or the Bartesian Duet as long as you add a cocktail capsule pack to your order. Presumably, if you are buying the machine, you’ll want the cocktail capsules anyway.

Bartesian Rewards Club: Get More for Your Buck

Bartesian also has a loyalty program that they’re calling, alternately, the Bartesian Club, the Bartesian Rewards Club, or Bartesian Mixologist Rewards. One way or the other, it doesn’t cost anything to sign up, and you get discounts. Basically, you earn 4 to 6 points per dollar you spend, plus get additional points for referring other customers, following Bartesian on Instagram, or just having a birthday. If you get a thousand points, you can redeem them for a $10 discount. There are also exclusive members-only tiers. Rewards are bigger if you’re a big spender. Here are the three membership tiers.

Earn 2,500 Points and Give $25 When You Refer a Friend

The biggest rewards bonus comes when you refer a friend who then buys a Bartesian or otherwise spends at least $150 on the site. Use the friend referral page here, and your friend will get a $25 discount using a Bertesian referral coupon code if they buy a Bartesian after using your link. You’ll also get 2,500 points on the Bartesian Rewards Club. Which is to say, you also get $25.

#Top #Bartesian #Discount #Codescoupons,shopping">Top Bartesian Discount Codes: 35% OffBartesian is the Keurig of cocktails. After trying several automatic cocktail makers on the market, it was the only cocktail maker I could see fitting into my normal routine. It works like any capsule-style device, but with booze. You fill the Bartesian’s glass bottles with your liquor of choice, make sure there’s water in the reservoir, plop in a cocktail capsule (these typically cost -3), choose your drink strength, press “mix,” and then a drink comes out. (If you’ve got kids, the Bartesian Professional version comes with a lock that will stymie curious fingers.)Do you need a Bartesian to make cocktails? Of course you don’t. You can dump tequila into sour mix anytime and call it a margarita. But perhaps you’d like to make an espresso martini, a blackberry margarita, and also a Long Island Iced Tea? The Bartesian is a sort of shortcut to a home bar, without having to store all the mixers—and a bit of a novelty. It will be fun, and silly, and the drinks are kind of fine in a Spring Break way: strong and sweet and with sometimes fun flavors. Don’t expect sophistication. Expect a bit of a party trick, the sort of thing that makes a summer a little more fun.You’ll, of course, want a Bartesian coupon to make that fun more accessible. Luckily, the current Bartesian discount codes are good for up to 35% off.Save up to 35% With a Bartesian Cocktail SubscriptionStandard pods on the Bartesian come in packs of 8, for  to . But if you know you plan to use the cocktail machine often—garden parties, art gallery openings, a really cool barber shop, an interesting home life, Friday afternoon margaritaville—the easiest way to save on the Bartesian pods is to sign up for a cocktail subscription. No Bartesian subscription discount codes are required. Subscription boxes always cost , so get the ones that’d be otherwise expensive for a 20% discount—then get additional tiered discounts of Bartesian depending on volume and frequency. If you order often or in large quatnities, this can add up to 35% off the regular price.Save 15% (Or More) When You Purchase a Cocktail BundleI can’t tell you what to do. But at current discounts on Bartesian cocktail bundles and add-ons, only a sucker buys a Bartesian as a standalone item. If you flip to the Bartesian bundles page, you can find multiple bundles that offer glassware and cocktail variety packs for about the same price as the machine by itself. The Mom Bundle in particular costs less than the Bartesian Pro machine by itself, but includes 8 margarita capsules and two glasses. As of April 2026, Bartesian is also offering a Mother’s Day deal, offering 0 off the Bartesian Pro or the Bartesian Duet as long as you add a cocktail capsule pack to your order. Presumably, if you are buying the machine, you’ll want the cocktail capsules anyway.Bartesian Rewards Club: Get More for Your BuckBartesian also has a loyalty program that they’re calling, alternately, the Bartesian Club, the Bartesian Rewards Club, or Bartesian Mixologist Rewards. One way or the other, it doesn’t cost anything to sign up, and you get discounts. Basically, you earn 4 to 6 points per dollar you spend, plus get additional points for referring other customers, following Bartesian on Instagram, or just having a birthday. If you get a thousand points, you can redeem them for a  discount. There are also exclusive members-only tiers. Rewards are bigger if you’re a big spender. Here are the three membership tiers.Earn 2,500 Points and Give  When You Refer a FriendThe biggest rewards bonus comes when you refer a friend who then buys a Bartesian or otherwise spends at least 0 on the site. Use the friend referral page here, and your friend will get a  discount using a Bertesian referral coupon code if they buy a Bartesian after using your link. You’ll also get 2,500 points on the Bartesian Rewards Club. Which is to say, you also get .#Top #Bartesian #Discount #Codescoupons,shopping

trying several automatic cocktail makers on the market, it was the only cocktail maker I could see fitting into my normal routine. It works like any capsule-style device, but with booze. You fill the Bartesian’s glass bottles with your liquor of choice, make sure there’s water in the reservoir, plop in a cocktail capsule (these typically cost $2-3), choose your drink strength, press “mix,” and then a drink comes out. (If you’ve got kids, the Bartesian Professional version comes with a lock that will stymie curious fingers.)

Do you need a Bartesian to make cocktails? Of course you don’t. You can dump tequila into sour mix anytime and call it a margarita. But perhaps you’d like to make an espresso martini, a blackberry margarita, and also a Long Island Iced Tea? The Bartesian is a sort of shortcut to a home bar, without having to store all the mixers—and a bit of a novelty. It will be fun, and silly, and the drinks are kind of fine in a Spring Break way: strong and sweet and with sometimes fun flavors. Don’t expect sophistication. Expect a bit of a party trick, the sort of thing that makes a summer a little more fun.

You’ll, of course, want a Bartesian coupon to make that fun more accessible. Luckily, the current Bartesian discount codes are good for up to 35% off.

Save up to 35% With a Bartesian Cocktail Subscription

Standard pods on the Bartesian come in packs of 8, for $20 to $25. But if you know you plan to use the cocktail machine often—garden parties, art gallery openings, a really cool barber shop, an interesting home life, Friday afternoon margaritaville—the easiest way to save on the Bartesian pods is to sign up for a cocktail subscription. No Bartesian subscription discount codes are required. Subscription boxes always cost $20, so get the ones that’d be otherwise expensive for a 20% discount—then get additional tiered discounts of Bartesian depending on volume and frequency. If you order often or in large quatnities, this can add up to 35% off the regular price.

Save 15% (Or More) When You Purchase a Cocktail Bundle

I can’t tell you what to do. But at current discounts on Bartesian cocktail bundles and add-ons, only a sucker buys a Bartesian as a standalone item. If you flip to the Bartesian bundles page, you can find multiple bundles that offer glassware and cocktail variety packs for about the same price as the machine by itself. The Mom Bundle in particular costs less than the Bartesian Pro machine by itself, but includes 8 margarita capsules and two glasses. As of April 2026, Bartesian is also offering a Mother’s Day deal, offering $100 off the Bartesian Pro or the Bartesian Duet as long as you add a cocktail capsule pack to your order. Presumably, if you are buying the machine, you’ll want the cocktail capsules anyway.

Bartesian Rewards Club: Get More for Your Buck

Bartesian also has a loyalty program that they’re calling, alternately, the Bartesian Club, the Bartesian Rewards Club, or Bartesian Mixologist Rewards. One way or the other, it doesn’t cost anything to sign up, and you get discounts. Basically, you earn 4 to 6 points per dollar you spend, plus get additional points for referring other customers, following Bartesian on Instagram, or just having a birthday. If you get a thousand points, you can redeem them for a $10 discount. There are also exclusive members-only tiers. Rewards are bigger if you’re a big spender. Here are the three membership tiers.

Earn 2,500 Points and Give $25 When You Refer a Friend

The biggest rewards bonus comes when you refer a friend who then buys a Bartesian or otherwise spends at least $150 on the site. Use the friend referral page here, and your friend will get a $25 discount using a Bertesian referral coupon code if they buy a Bartesian after using your link. You’ll also get 2,500 points on the Bartesian Rewards Club. Which is to say, you also get $25.

#Top #Bartesian #Discount #Codescoupons,shopping">Top Bartesian Discount Codes: 35% Off

Bartesian is the Keurig of cocktails. After trying several automatic cocktail makers on the market, it was the only cocktail maker I could see fitting into my normal routine. It works like any capsule-style device, but with booze. You fill the Bartesian’s glass bottles with your liquor of choice, make sure there’s water in the reservoir, plop in a cocktail capsule (these typically cost $2-3), choose your drink strength, press “mix,” and then a drink comes out. (If you’ve got kids, the Bartesian Professional version comes with a lock that will stymie curious fingers.)

Do you need a Bartesian to make cocktails? Of course you don’t. You can dump tequila into sour mix anytime and call it a margarita. But perhaps you’d like to make an espresso martini, a blackberry margarita, and also a Long Island Iced Tea? The Bartesian is a sort of shortcut to a home bar, without having to store all the mixers—and a bit of a novelty. It will be fun, and silly, and the drinks are kind of fine in a Spring Break way: strong and sweet and with sometimes fun flavors. Don’t expect sophistication. Expect a bit of a party trick, the sort of thing that makes a summer a little more fun.

You’ll, of course, want a Bartesian coupon to make that fun more accessible. Luckily, the current Bartesian discount codes are good for up to 35% off.

Save up to 35% With a Bartesian Cocktail Subscription

Standard pods on the Bartesian come in packs of 8, for $20 to $25. But if you know you plan to use the cocktail machine often—garden parties, art gallery openings, a really cool barber shop, an interesting home life, Friday afternoon margaritaville—the easiest way to save on the Bartesian pods is to sign up for a cocktail subscription. No Bartesian subscription discount codes are required. Subscription boxes always cost $20, so get the ones that’d be otherwise expensive for a 20% discount—then get additional tiered discounts of Bartesian depending on volume and frequency. If you order often or in large quatnities, this can add up to 35% off the regular price.

Save 15% (Or More) When You Purchase a Cocktail Bundle

I can’t tell you what to do. But at current discounts on Bartesian cocktail bundles and add-ons, only a sucker buys a Bartesian as a standalone item. If you flip to the Bartesian bundles page, you can find multiple bundles that offer glassware and cocktail variety packs for about the same price as the machine by itself. The Mom Bundle in particular costs less than the Bartesian Pro machine by itself, but includes 8 margarita capsules and two glasses. As of April 2026, Bartesian is also offering a Mother’s Day deal, offering $100 off the Bartesian Pro or the Bartesian Duet as long as you add a cocktail capsule pack to your order. Presumably, if you are buying the machine, you’ll want the cocktail capsules anyway.

Bartesian Rewards Club: Get More for Your Buck

Bartesian also has a loyalty program that they’re calling, alternately, the Bartesian Club, the Bartesian Rewards Club, or Bartesian Mixologist Rewards. One way or the other, it doesn’t cost anything to sign up, and you get discounts. Basically, you earn 4 to 6 points per dollar you spend, plus get additional points for referring other customers, following Bartesian on Instagram, or just having a birthday. If you get a thousand points, you can redeem them for a $10 discount. There are also exclusive members-only tiers. Rewards are bigger if you’re a big spender. Here are the three membership tiers.

Earn 2,500 Points and Give $25 When You Refer a Friend

The biggest rewards bonus comes when you refer a friend who then buys a Bartesian or otherwise spends at least $150 on the site. Use the friend referral page here, and your friend will get a $25 discount using a Bertesian referral coupon code if they buy a Bartesian after using your link. You’ll also get 2,500 points on the Bartesian Rewards Club. Which is to say, you also get $25.

#Top #Bartesian #Discount #Codescoupons,shopping

Post Comment